This site is intended for US Health Care Professionals only.
PROVENGE is immunotherapy for asymptomatic
or minimally symptomatic metastatic castrate
resistant prostate cancer (mCRPC)
At the time of
of CRPC patients may be eligible
Treat Early - make sure your patients
take advantage of the PROVENGE window
Dendreon ON Call – Supporting Your Practice and Your Patients
Personalized Support For Your PROVENGE Patients
Is Just A Call Away...We Have You Covered
Sustained Immune Response And Short Duration Of Treatment*
Copyright © 2017 Dendreon Pharmaceuticals LLC. All rights reserved.
PRV.0136.USA.16-PXA0015 USA 16 v1.1
This content is intended for US health care professionals only and by clicking YES I am confirming that I am a health care provider.
NO, I am not a HCP. Go to PROVENGE.com
Your e-mail has been sent. To learn more about PROVENGE, please see the Full Prescribing Information.
To learn more about PROVENGE, please see the Full Prescribing Information.